SLN360
Silence Therapeutics
[]
$sln - silence therapeutics presents new analysis from sln360 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting 
Follow for the latest #healthcare #stockmarket tweets. Visit https://t.co/wA5OfUn0Ee to try our powerful investing tools.